Quantum BioPharma Ltd. reported its audited financial and operational results for the fourth quarter and year ended December 31, 2025, highlighting a strong cash position, reduced operating expenses, and progress in its multiple sclerosis drug candidate and unbuzzd™ product. The company maintains sufficient working capital for operations beyond January 2028 and reported a reduction in trade payables by approximately 50%.
Key takeaways
Cash on hand and fair market value of digital assets as of the filing date is $11.3 million USD, with management believing sufficient cash exists to sustain basic operations beyond January 2028.
Operating Expenses for the year ended December 31, 2025, were $15.3 million USD, a reduction from $16.1 million USD in 2024, an improvement of approximately 5%.
Trade and other payables were reduced by approximately 50%, from $4.1 million on December 31, 2025, to $2.0 million as of the filing date.
External research and development fees decreased to $2.8 million USD for the year ended December 31, 2025, from $6.1 million USD in 2024.
Phase 1 oral toxicity studies for multiple sclerosis drug candidate Lucid-21-302 are complete, showing no toxicity or significant side effects, with an IND filing for Phase 2 planned for H1 2026.
Terry Lynch resigned from the board of directors effective March 27, 2026, due to constraints on his ability to dedicate adequate time to Quantum.